Nektar TherapeuticsNKTR
NKTR
About: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Employees: 61
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
620% more call options, than puts
Call options by funds: $885K | Put options by funds: $123K
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
8% more funds holding
Funds holding: 145 [Q4 2024] → 157 (+12) [Q1 2025]
5.5% less ownership
Funds ownership: 72.04% [Q4 2024] → 66.54% (-5.5%) [Q1 2025]
13% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 48
32% less capital invested
Capital invested by funds: $124M [Q4 2024] → $84.2M (-$39.4M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$30
249%
upside
Avg. target
$30
249%
upside
High target
$30
249%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Jefferies Roger Song | 249%upside $30 | Buy Upgraded | 11 Apr 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
3 days ago
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
Results from Nektar Therapeutics' phase 2b REZOLVE-AD study, using REZPEG for the treatment of patients with atopic dermatitis, are expected in June 2025. The global atopic dermatitis treatment market is projected to reach $28.7 billion by 2031. NKTR's results from phase 2b REZOLVE-AA, using REZPEG for the treatment of patients with Alopecia Areata, expected in the 2nd half of 2025.
Neutral
GlobeNewsWire
4 days ago
AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance
Brand emphasizes absolute transparency and traceability, sourcing single-ingredient food from small artisan producers Brand emphasizes absolute transparency and traceability, sourcing single-ingredient food from small artisan producers
Neutral
PRNewsWire
1 month ago
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
SAN FRANCISCO , May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq Headquarters in New York City on May 20, 2025: H.C.
Negative
Zacks Investment Research
1 month ago
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Neutral
Seeking Alpha
1 month ago
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Corinne Franklin – Investor Relations Howard Robin – President and Chief Executive Officer Jonathan Zalevsky – Chief Research and Development Officer Sandra Gardiner – Chief Financial Officer Conference Call Participants Dominic Risso-Gill – Piper Sandler Julian Harrison – BTIG Jay Olson – Oppenheimer Roger Song – Jefferies Mayank Mamtani – B. Riley Securities Arthur He – H.C.
Negative
Zacks Investment Research
1 month ago
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.
Neutral
PRNewsWire
1 month ago
Nektar Therapeutics Reports First Quarter 2025 Financial Results
SAN FRANCISCO , May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024.
Neutral
PRNewsWire
1 month ago
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.
Negative
Zacks Investment Research
1 month ago
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Negative
Zacks Investment Research
2 months ago
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Charts implemented using Lightweight Charts™